GlassScriptPhysician profile
Brent T Stewart
NPI 1548374085
$9,906.81
in general payments reported to CMS, 2019-2025
34 companies · $1,055 in 2025
The $1,055 reported for 2025 was more than what a typical Pain Medicine (Anesthesiology) provider received nationally (typical 2025 total: $458).
See the full distribution for Pain Medicine (Anesthesiology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,318 · 2020: $1,067 · 2021: $1,389 · 2022: $1,713 · 2023: $1,476 · 2024: $1,888 · 2025: $1,055.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,420.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,419.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $2,540.76 | 2019-2025 | Xtampza, Belbuca |
| Boston Scientific Corporation | $2,112.74 | 2019-2025 | Wavewriter Alpha Prime 16, General - Pain Management, Clinical Trial Product |
| Pfizer INC. | $787.41 | 2019-2025 | |
| Foundation Fusion Solutions, LLC | $639.97 | 2024-2025 | |
| Horizon Therapeutics Plc | $545.88 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $530.06 | 2019-2025 | Relistor |
| Scilex Pharmaceuticals INC. | $325.03 | 2022-2024 | Ztlido |
| Biodelivery Sciences International, INC. | $291.18 | 2019-2021 | |
| Abbvie INC. | $226.38 | 2021-2025 | Ubrelvy |
| Vertos Medical, INC. | $212.87 | 2022 | |
| Spr Therapeutics, INC | $209.22 | 2024-2025 | Sprint Pns System |
| Teva Pharmaceuticals USA, INC. | $158.02 | 2019-2021 | |
| Lilly USA, LLC | $123.13 | 2021-2022 | |
| Virtus Pharmaceuticals LLC | $121.93 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $117.16 | 2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $113.13 | 2021-2023 | Gralise |
| Biohaven Pharmaceuticals, INC. | $108.94 | 2020-2021 | |
| Supernus Pharmaceuticals, INC. | $102.70 | 2019 | |
| Amgen INC. | $96.88 | 2019-2022 | |
| Redhill Biopharma INC. | $87.19 | 2020-2021 | |
| Medtronic, INC. | $72.56 | 2023 | Intellis Adaptivestim |
| Mdd US Operations, LLC | $64.01 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $48.79 | 2019-2021 | |
| Daiichi Sankyo INC. | $48.57 | 2019 | |
| Bioventus LLC | $42.89 | 2019-2023 | Gelsyn-3 |
| Takeda Pharmaceuticals U.S.A., INC. | $41.51 | 2019 | |
| Inari Medical, INC. | $30.15 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Valinor Pharma, LLC | $21.74 | 2023 | Movantik |
| Zyla Life Sciences, INC. | $18.47 | 2020 | |
| Relievant Medsystems, INC. | $16.38 | 2022 | |
| Novartis Pharmaceuticals Corporation | $14.71 | 2019 | |
| Depuy Synthes Sales INC. | $13.65 | 2019 | |
| Biogen, INC. | $11.72 | 2022 | |
| Assertio Therapeutics, INC. | $11.08 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brent Stewart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.